Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study

Hakeam A. Hakeam, MS Pharm, BCPS1,2, Zainab Al Duhailib, MBBS, EDIC3,4, Muhannad Alsemari, MBBS5, Reem M. Alwaibah, PharmD6, Madhawi F. Al Shannan, PharmD6, and Munirah Shalhoub, PharmD6

Abstract
Enoxaparin is indicated for thromboprophylaxis in non-orthopedic surgical patients at a fixed dose of 40 mg daily. According to the US Food and Drug Administration’s enoxaparin prescribing information, this dose exposes low-weight patients (males < 57 kg, females < 45 kg) to a higher risk of bleeding. This study aimed to determine the rate of achieving a prophylactic peak anti-factor Xa (AFXa) level in low-weight surgical patients using enoxaparin 30 mg daily. Low-weight patients admitted for abdominopelvic or noncardiac thoracic surgery from May 2018 to May 2019 were prospectively studied. After receiving daily enoxaparin 30 mg, peak AFXa levels were assessed for achieving a prophylactic level (0.2-0.5 IU/mL). In 121 patients, the proportion of achieving a prophylactic peak AFXa level was 66.1%. More females (84.8%) achieved a prophylactic level compared to males (54.7%, \( P = .001 \)). All out-of-range peak AFXa levels (33.9%) were sub-prophylactic. The median peak AFXa level was lower in males (0.24 [0.1-0.47] IU/mL) than females (0.31 [0.1-0.5] IU/mL; \( P < .001 \)). On univariate analysis, female sex and weight were associated with achieving a prophylactic peak AFXa level. On multivariate analysis, only female sex was independently associated with an adequate prophylactic AFXa level (odds ratio 3.17, 95% CI: 1.32-11.94; \( P = .014 \)). Four venous thromboembolism events (3.3%) were observed in patients with sub-prophylactic peak AFXa levels (9.7%). Two-thirds of low-weight surgical patients achieved a prophylactic peak AFXa level using daily enoxaparin 30 mg. This dose is likely to provide adequate thromboprophylaxis in low-weight females.

Keywords
enoxaparin, low-molecular-weight heparin, low-weight, thromboprophylaxis

Date received: 27 March 2020; revised: 01 May 2020; accepted: 10 May 2020.

Introduction
Low-molecular-weight heparin (LMWH), a class of parenteral anticoagulants, is recommended by the American College of Chest Physicians guidelines for pharmacological prophylaxis of venous thromboembolism (VTE) in patients with or without cancer who are undergoing surgery.1 A meta-analysis of 8 trials demonstrated a 70% reduction in clinical VTE in surgical patients who received LMWH prophylaxis compared to no prophylaxis.5 This marked reduction in VTE was accompanied by an approximately 2-fold increase in the risks of major bleeding and wound haematoma after surgery.

Enoxaparin is a LMWH approved by both the US Food and Drug Administration (FDA) and the European Medication Agency for VTE prophylaxis at a daily dose of 40 mg subcutaneously for abdominal, pelvic, and lung surgery.2,4 The

1 Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre
2 College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
4 Department of Critical Care Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
5 Department of Surgery, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
6 College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

Corresponding Author:
Hakeam A. Hakeam, Pharmaceutical Care Division, King Faisal Specialist Hospital & Research Centre, College of Medicine, Alfaisal University, P.O. Box 3354 MBC#11, Riyadh 11211, Saudi Arabia.
Email: hakeam@kfshrc.edu.sa
effectiveness and safety of fixed-dose enoxaparin in preventing VTE in non-orthopedic surgery have been demonstrated in many randomized trials.5,6 Due to its predictable pharmacokinetics and pharmacodynamics, the administration of fixed doses of enoxaparin for prophylaxis requires no monitoring or adjustment for weight, except in patients with morbid obesity or renal insufficiency.7

Direct enoxaparin monitoring is inapplicable in clinical practice; therefore, anti-factor Xa (AFXa) levels are measured as a surrogate marker to reflect the adequacy of thromboprophylaxis.8 AFXa levels are inversely related to the development of VTE, whereas the risk of bleeding increases with AFXa levels above 0.8 to 1.0 IU/mL.9,10 AFXa peak levels ranging from 0.2 to 0.5 IU/mL at 4 hours after subcutaneous enoxaparin administration are considered adequate for VTE prophylaxis.8,11,12

The US FDA-approved prescribing information for enoxaparin recommends careful observation for signs and symptoms of bleeding in low-weight patients receiving 40 mg for thromboprophylaxis.5 Compared with average-weight subjects, a single dose of enoxaparin 40 mg resulted in 52% and 27% higher AFXa levels in low-weight women (<45 kg) and low-weight men (<57 kg), respectively.3 However, no specific dose of enoxaparin was suggested for VTE prophylaxis in these low-weight individuals.

Substantial weight loss is prevalent among patients undergoing surgery for many solid tumors and inflammatory bowel diseases (IBD). Preoperatively, the rate of cachexia exceeds 19% in patients with cancer, whereas 11% of patients with Crohn’s disease are considered underweight.13,14 Low-weight surgical patients are often extremely ill, with a high risk of VTE secondary to their underlying disease or prolonged hospitalisation.13,15,16

To date, no prospective study has examined whether prophylactic AFXa levels are achieved in low-weight patients receiving a substandard prophylactic enoxaparin dose. This study aimed to determine the percentage of low-weight surgical patients achieving peak AFXa levels appropriate for thromboprophylaxis after subcutaneous administration of a fixed dose of enoxaparin 30 mg once per day.

Methods

A prospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Riyadh, in accordance with the amended Declaration of Helsinki and after receiving institutional review board approval (RAC#2181086). The inclusion criteria were as follows: age > 18 years, low bodyweight (<57 kg in males and <45 kg in females), and admission for abdominal, pelvic, or noncardiac thoracic surgery from May 2018 to May 2019. The exclusion criteria were as follows: pregnancy, renal impairment (glomerular filtration rate of <60 mL/min/1.72 m², calculated using the Modification of Diet in Renal Disease equation), known bleeding disorder or history of thrombosis, <3 consecutive doses of enoxaparin, development of heparin-induced thrombocytopenia or a platelet count of <50 000/µL, or bodyweight <30 kg.

On admission to the hospital, low-weight patients began VTE prophylaxis with subcutaneous enoxaparin (Sanofi-Aventis) 30 mg once daily, which was administered at a scheduled time of 21:00. Patients fulfilling the inclusion and exclusion criteria were consented for enrollment in the study. Patients admitted multiple times to our surgical service were enrolled for their first hospital stay only and sampled for one AFXa level.

Peak AFXa level was measured 4 hours after the third dose of enoxaparin had been administered subcutaneously; each dose was given once daily. If a peak AFXa level was sampled before surgery, it was considered “preoperatively assessed,” while if it was sampled after surgery, it was considered “postoperatively assessed.” AFXa levels obtained from patients admitted for surgical intervention but who received conservative management were considered “preoperatively assessed” during the data analysis. The daily enoxaparin dose was changed to 40 or 20 mg for sub- or supra-prophylactic peak AFXa levels, respectively. Anti-factor Xa levels were assessed using the chromogenic-based liquid STA assay for unfractionated heparin and LMWH (Diagnostica, STAGO, S.A.S).

Patient demographics and clinical characteristics including the Caprini score were recorded.17 The surgical diagnosis (i.e., indication for surgery), underlying disease state (malignancy or IBD), time of initiating enoxaparin prophylaxis, and duration of enoxaparin prophylaxis were also recorded. Bilirubin level was obtained on the day of blood sampling for AFXa level.

Patients were followed for 4 weeks to assess whether they developed VTE or bleeding. Those who did not undergo surgery were followed for 4 weeks after hospital admission and those who underwent surgery were followed for 4 weeks postoperatively. Patients discharged from the hospital before the end of the 4-week follow-up period were evaluated at the surgical clinic.
defined according to the International Society on Thrombosis and Haemostasis (ISTH) definition for surgical patients. Bleeding that did not meet this definition was considered clinically relevant non-major bleeding (CRNMB) and recorded as well.

**Statistical Analysis**
We enrolled all patients who met the inclusion and exclusion criteria over 1 year. A sample size calculation was performed to ensure enrolment of a representative number of patients. In the absence of a comparable study in the literature for sample calculation, the number of low-weight patients admitted for surgery to our institution in the preceding year was used for this purpose (165 patients). Therefore, the minimum sample size required to estimate achievement of a prophylactic AFXa level, with a margin of error of 5% and 95% confidence interval (CI), was 115 patients.

Normally distributed data were expressed as mean ± SD. Non-normally distributed continuous data were reported as medians with ranges (minimum to maximum or interquartile range). Student t test was used to compare the means of normally distributed data, while the Mann–Whitney U test was used to compare the differences between continuous and non-normally distributed data. The χ² test or Fisher’s exact test (for cell counts < 5) was used to examine associations between categorical variables reported as counts and percentages. Spearman ρ test was used to assess correlations. Univariate analysis using logistic regression analysis with the forced entry technique was used to assess the associations for predetermined covariates. Covariates with a P < .1 during univariate analysis were considered for the multivariate logistic regression model. Statistical significance was set at P < .05. Statistical analysis was performed using SPSS, version 20.0 IBM.

**Results**

**Patient and Treatment Characteristics**

Of 158 eligible patients, 121 were enrolled in the study, with the majority of exclusions due to renal impairment (17 patients). The remaining exclusions were due to a history of hematologic or thrombotic disease (7 patients), failure to complete 3 consecutive doses of enoxaparin (10 patients), and consent rejection (3 patients). The demographic and clinical characteristics of the included patients are presented in Table 1. Males constituted 61.9% of the cohort, and 57.9% of the study patients had a malignancy. Among the 51 cancer-free patients, 22 (18.2% of the total cohort) had a diagnosis of IBD. The majority of the patients were classified into “high risk” category for VTE according to their Caprini score. Eighteen (14.8%) patients were admitted to the hospital for possible surgery but received only conservative management. Body-weight differed according to sex: mean weight was lower in females (39.2 ± 5.8 kg) than males (48.0 ± 6.2 kg, P < .001), while the mean BMI was comparable between females (17.1 ± 3.0 kg/m²) and males (17.3 ± 2.2 kg/m²; P = .773).

| Table 1. Clinical Characteristics and Demographics of the Study Cohort. |
|---------------------------------------------------------------|
| Characteristics and demographics | No. (%) | n = 121 |
| **Sex** | | |
| Female | 46 (38) | |
| Male | 75 (61.9) | |
| **Age (mean ± SD), years** | 45.4 ± 19.3 | |
| **Weight (mean ± SD), kg** | 44.7 ± 7.43 | |
| **Female (mean ± SD), kg; median (range)** | 39.2 ± 5.8; 40.6 (30.0-45.2) | |
| **Male (mean ± SD), kg; median (range)** | 48.0 ± 6.2; 48.5 (30.1-56.8) | |
| **BMI (mean ± SD); median (range), kg/m²** | 17.2 ± 2.5; 17.6 (9.9-26.6) | |
| **Female (mean ± SD); median (range), kg/m²** | 17.1 ± 3.0; 17.4 (10.4-26.6) | |
| **Male (mean ± SD); median (range), kg/m²** | 17.3 ± 2.2; 17.6 (9.9-23.4) | |
| **Disease state** | | |
| Malignancy | 70 (57.9) | |
| Inflammatory bowel disease | 22 (18.2) | |
| Caprini score, median (range) | 6 (1-11) | |
| Low risk (0-1 points) | 29 (24) | |
| Moderate risk (2 points) | 17 (14) | |
| High risk (3-4 points) | 50 (41.3) | |
| Highest risk (≥5 points) | 25 (20.7) | |
| **Surgical intervention** | | |
| Lung and noncardiac thoracic surgery | 14 (11.5) | |
| Colorectal surgery | 38 (31.4) | |
| Cytoreductive surgery and HIPEC | 7 (5.7) | |
| Upper gastrointestinal tract | 16 (13.2) | |
| Genitourinary | 5 (4.1) | |
| Gynecological | 8 (6.6) | |
| Other | 15 (12.3) | |
| Conservative management | 18 (14.8) | |
| Hospital stay (mean ± SD); median (range), days | 13.1 ± 13.5; 8 (3-74) | |
| Bilirubin level (mean ± SD); median (range), µmol/L | 13.4 ± 3.6; 6.8 (2.5-334) | |

**Abbreviations:** BMI, body mass index; HIPEC, hyperthermic intraperitoneal chemotherapy.

The median time to start enoxaparin VTE prophylaxis postoperatively was 17.7 hours (6-53 hours); 42 (41.1%) of the 102 patients who underwent surgery received enoxaparin within the first 12 hours postoperatively. The median calculated enoxaparin dose was 0.66 mg/kg and was higher in females (0.73 [0.56-1.01] mg/kg) than in males (0.61 [0.40-0.90] mg/kg, P < .01).

**Outcomes**

Overall, 80 (66.1%) of the 121 study patients achieved a prophylactic peak AFXa level (Table 2). The proportion of achieving a prophylactic AFXa level per sex was higher in female patients (84.8%) compared to male patients (54.7%, P = 0.001). Table 3 shows the clinical characteristics of patients who did or did not achieve a prophylactic peak AFXa level.
Table 2. Outcome Characteristics for the Study Cohort.

| Peak AFXa levels | n = 121 |  |
|------------------|---------|---|
| Preoperatively assessed | 49 (40.4) |  |
| Postoperatively assessed | 72 (59.5) |  |
| Prophylactic (0.2-0.5 IU/mL) | 80 (66.1) |  |
| Sub-prophylactic (<0.2 IU/mL) | 41 (33.8) |  |
| Supra-prophylactic (>0.5 IU/mL) | 0 (0) |  |
| Overall bleeding events | 7 (5.8) |  |
| VTE events | 4 (3.3) |  |

Abbreviations: AFXa, anti-factor Xa; VTE, venous thromboembolism.

Table 3. Comparisons of Patient Characteristics With Prophylactic and Sub-prophylactic AFXa Levels.

| Characteristics | Prophylactic AFXa level | Sub-prophylactic AFXa level | P |
|----------------|-------------------------|-----------------------------|---|
| Age, mean ± SD, years | 44.5 ± 19.0 | 47.2 ± 19.9 | .458 |
| Sex | 0.001 |
| Male | 41 (51.2) | 34 (82.9) |
| Female | 39 (48.8) | 7 (17.1) |
| Morphometric features |  |
| BMI, mean ± SD, kg/m² | 17.4 ± 2.6 | 16.9 ± 2.3 | .36 |
| Weight, mean ± SD, kg | 43.6 ± 7.7 | 46.8 ± 6.3 | .025 |
| Disease state |  |
| Malignancy | 48 (60) | 22 (53.6) | .554 |
| Inflammatory bowel disease | 11 (13.75) | 11 (26.8) | .077 |
| Measurement of AFXa levels | 0.813 |
| Postoperatively assessed | 47 (58.7) | 25 (60.9) |
| Preoperatively assessed | 33 (41.25) | 16 (39) |
| Bilirubin, median (IQR), mg/dL | 5.6 (3.1-9.2) | 8.2 (6.3-13.8) | .22 |
| Hospital stay, median (range), days | 8 (3-32) | 9 (3-48) | .59 |
| VTE events | 0 | 4 (9.7) | .012 |
| Bleeding events | 5 (6.25) | 2 (4.8) | 1.0 |

Abbreviations: AFXa, anti-factor Xa; BMI, body mass index; IQR: interquartile range; VTE, venous thromboembolism.

Discussion

In this prospective study, 66% of low-weight, non-orthopedic surgical patients achieved prophylactic peak AFXa levels with a fixed dose of once daily subcutaneous enoxaparin 30 mg. At this dose, bodyweight was weakly inversely correlated with the achievement of a prophylactic level of peak AFXa in our low-weight patients (males <57 kg and females <45 kg). Dosing with subcutaneous enoxaparin 30 mg per day produced a median dose-to-weight ratio of 0.66 mg per kg in our low-weight patients.
A recent retrospective study of 35 low-weight patients (<55 kg) demonstrated a slightly higher proportion (74\%) of adequate AFXa levels. However, 22\% of the patients in that study developed supra-prophylactic AFXa levels, unlike our study, which had no supra-prophylactic levels. This difference could be explained by the variability of enoxaparin doses used in the retrospective study, with majority of patients received 30 mg once daily. The median dose of enoxaparin administered in the retrospective study (0.6 mg per kg) was similar to that in our study (0.66 mg per kg). Both median doses are lower than that used by Rojas et al who prospectively administered 40 mg enoxaparin to 56 patients weighing < 55 kg, for a calculated median dose of 0.8 mg per kg. Rojas et al reported that 60.7\% of their patients had an AFXa of ≥ 0.5 IU/mL. This high percentage of supra-prophylactic AFXa levels may increase the risk of bleeding in surgical patients, especially if enoxaparin is administered close to surgery.2

The ENOXACAN study reported an 18\% rate of bleeding in patients undergoing abdominal and pelvic surgery, all of whom received enoxaparin 40 mg as thromboprophylaxis. Patients with a BMI as low as 15.9 kg/m² were included in that trial, and no reductions in enoxaparin dose were applied. This might explain the higher bleeding rates in the ENOXACAN study compared to our study. Both the ENOXACAN study and our study excluded renally impaired patients. We excluded patients with any stage of renal insufficiency because of the lack of evidence supporting the safety of enoxaparin thromboprophylaxis in low-weight patients who also have impaired renal function.

A prospective study of 2 prophylactic doses of enoxaparin, 40 mg daily and 30 mg twice daily administered to average weight cancer patients, demonstrated the association of female sex with adequacy of peak AFXa level.21 Another study of obese patients who received enoxaparin VTE prophylaxis (88.5\% of patients received 40 mg daily) found that female sex was associated with higher AFXa level.22 This sex effect disparity for AFXa level was also observed in our study, where a higher proportion of females achieved the prophylactic range of AFXa. Therefore, females are more likely than males to achieve adequate prophylaxis across a range of body weights. The higher rate of adequate prophylaxis observed in females could be explained by their lower body water content and plasma volume compared to males.23 As a sodium salt, enoxaparin is a hydrophilic compound that distributes primarily into the vascular space.10,24 Accordingly, enoxaparin would be more concentrated in smaller aqueous environments, such as blood. Another possible explanation is that sex-dependent differences in biotransformation have been observed for some

**Table 4.** Univariate and Multivariate Logistic Regression Analyses of the Relative Achievement of a Prophylactic AFXa Level With Baseline Variables.

| Sex                | Univariate logistic regression odds ratio, 95\% CI | β   | P      | Multivariate logistic regression odds ratio, 95\% CI | β   | P      |
|--------------------|-----------------------------------------------|-----|--------|---------------------------------------------------|-----|--------|
| Female             | 4.63 (1.83-11.64)                              | 1.53 | .001   | 3.17 (1.32-11.94)                                  | 1.38 | .014   |
| Male               | 0.21 (0.08-0.54)                               | -1.53 | .001   |                                                   |     |        |
| Age                | 0.99 (0.97-1.01)                               | -0.007 | .45  |                                                   |     |        |
| Weight             | 0.93 (0.88-0.99)                               | -0.064 | .028 | 0.98 (0.92-1.05)                                  | -0.016 | .63 |
| BMI                | 1.07 (0.92-1.24)                               | 0.07 | .35  |                                                   |     |        |
| BMI ≥ 18.5, kg/m²  | 1.81 (0.75-4.33)                               | 0.59 | .18  |                                                   |     |        |
| BMI < 18.5, kg/m²  | 0.55 (0.23-1.32)                               | -0.59 | .18  |                                                   |     |        |
| Diseases state     |                                               |     |        |                                                   |     |        |
| IBD                | 0.43 (0.17-1.112)                              | -0.833 | .082 | 0.43 (0.16-1.18)                                  | -0.73 | .1 |
| Cancer             | 1.29 (0.66-2.76)                               | 0.259 | .504 |                                                   |     |        |
| Time of measurement of AFXa level |       |     |        |                                                   |     |        |
| Postoperatively assessed | 0.91 (0.42-1.96)     | -0.093 | .81  |                                                   |     |        |
| Preoperatively assessed | 1.09 (0.5-2.36) | 0.093 | .81  |                                                   |     |        |
| Bilirubin          | 0.98 (0.954-1.013)                             | 0.20 | .27  |                                                   |     |        |

Abbreviations: AFXa, anti-factor Xa; BMI, body mass index; IBD, inflammatory bowel disease.

**Figure 1.** Patient weight versus anti-factor-Xa level in low-weight surgical patients receiving enoxaparin 30 mg.
drugs, including heparin. As a heparin derivative, enoxaparin might undergo lower clearance in females compared to males.\textsuperscript{25} Although in our study, the mean weight of females was lower than that of males, even when we limited our analysis to only patients <45 kg in both sexes, the percentage of achieving a prophylactic peak AFXa level remained higher in females than males.

Based on the World Health Organization classification, adults with a BMI of <18.5 kg/m\(^2\) are considered underweight.\textsuperscript{26} In our study, the likelihood of achieving a prophylactic level of peak AFXa did not differ between underweight patients and those with a BMI \(\geq 18.5\) kg/m\(^2\). Moreover, no association was observed in our study between BMI and achievement of a prophylactic AFXa level. Therefore, for patients with an extremely low weight, lowering the dose of prophylactic enoxaparin according to weight rather than BMI is preferred. When prescribing or dispensing enoxaparin, clinicians should be cognizant that “underweight” and “low-weight” are not interchangeable terms. Of note, the definition of low bodyweight was inconsistent among studies assessing enoxaparin prophylaxis, with <55 kg set as a cutoff weight in some studies, irrespective of patient sex.\textsuperscript{19,20} A prospective study found a significant increase in bleeding risk among patients receiving enoxaparin for VTE treatment and weighing <55 kg.\textsuperscript{27} However, that study assessed a therapeutic dose of enoxaparin (1 mg per kg every 12 hours) for the treatment of an established VTE. Therefore, extrapolating outcomes of therapeutic doses of enoxaparin to prophylactic doses is impractical.

The effectiveness of a fixed-dose enoxaparin strategy for VTE prophylaxis has been questioned by many experts, who recommended either weight-based dosing regimens or real-time monitoring of AFXa levels as alternatives.\textsuperscript{20,23} Although the majority of patients in our study had a peak AFXa level consistent with adequate VTE prophylaxis using a fixed-dose strategy, our patients’ weights were within a relatively narrow range: 30 to 57 kg for males and 30 to 45 kg for females.

Significant weight loss is commonly observed in patients transferred to tertiary care centers for surgical management. Guidelines recommend 7 to 10 days of preoperative parenteral nutrition (PN) in severely malnourished patients with IBD or cancer to reduce the risk of postoperative complications.\textsuperscript{28,29} However, the need for central venous access for PN infusions predisposes to catheter-related thrombosis, PE, and vena cava syndrome.\textsuperscript{30} In our study, two subclavian DVTs developed in patients receiving PN via a central catheter, representing 50% of all VTE events. One of these upper extremity DVTs developed in a patient receiving PN preoperatively. Therefore, the real-world effectiveness of achieving prophylactic AFXa levels in surgical patients should be assessed in the context of the entire hospital stay. Of note, we found no difference between the AFXa levels obtained pre- and postoperatively.

Our study had some limitations. Firstly, it lacked a control arm, such as patients receiving enoxaparin 40 mg. However, we chose not to expose our low-weight surgical patients, who are prone to bleeding, to 40 mg of enoxaparin, which could be contrary to the US FDA label advice. Secondly, we did not reassess the AFXa levels after increasing the enoxaparin dose in patients with sub-prophylactic peak AFXa levels, as we were unsure whether these patients would remain hospitalized long enough to remeasure their AFXa levels. Thirdly, we reported the rate of VTE development in our cohort; however, we want to stress that the study was not powered to detect a difference between patients who achieved and those who did not achieve the prophylactic AFXa range.

Although the majority of low-weight patients received adequate thromboprophylaxis with a daily dose of enoxaparin 30 mg, one-third of the patients did not achieve the prophylactic AFXa range. Therefore, we recommend that clinicians monitor peak AFXa levels when using this fixed dose of enoxaparin in this patient population, especially in males.

In conclusion, this prospective study demonstrated that two-thirds of low-weight, non-orthopedic surgical patients achieved a prophylactic peak AFXa level with a fixed-dose of enoxaparin 30 mg once daily. With this dose, low-weight females (<45 kg) were more likely than males to achieve peak AFXa levels considered adequate for thromboprophylaxis.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Hakeam A. Hakeam \(\textcolor{#f00}{\text{https://orcid.org/0000-0002-6979-0966}}\)

References

1. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):227-277. doi:10.1378/chest.11-2297
2. Mismetti P, Laporte S, Darwin JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88(7):913-930. doi:10.1046/j.0007-1323.2001.01800.x
3. Food and Drug Administration. FDA approved drug products/ enoxaparin In: Drugs@FDA. 2019. https://www.accessdata.fda.gov/scripts/cder/dfaim/index.cfm?event=overview.process&ApplNo=020164Accessed
4. Lovenox Article 30 Referral Assessment report. In: Procedure Number: EMEA/H/A-30/1429. European Medicines Agency. 2017. Accessed December 18, 2019. https://www.ema.europa.eu/en/documents/referral/lovenox-article-30-referral-assessment-report_en.pdf
5. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099-1103.
6. Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum. 1999;42(2):196-202; discussion 202-3. doi:10.1007/bf02237127

7. Nutescu EA, Spinler SA, Wittkowski A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064-1083. doi:10.1348/aph.11l194

8. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62(3):940-944.

9. Pannucci CJ, Rondina MT. Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively? Surgery. 2017;161(2):329-331. doi:10.1016/j.surg.2016.07.038

10. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001;21(2):218-234. doi:10.1592/phco.21.2.218.34112

11. Wei MY, Ward SM. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis. Hematol Rep. 2015;7(4):5844. doi:10.4081/hr.2015.5844

12. Lapasota M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799-807.

13. Fukuda Y, Yamamoto K, Hirao M, et al. Prevalence of malnutrition among gastric cancer patients undergoing gastrectomy and optimal preoperative nutritional support for preventing surgical site infections. Ann Surg Oncol. 2015;22(3):778-785. doi:10.1245/s10434-015-4820-9

14. McKenna NP, Habermann EB, Lightner AL, Mathis KL. Body mass index: implications on disease severity and postoperative complications in patients with Crohn’s disease undergoing abdominal surgery. Surgery. 2019;166(4):703-708. doi:10.1016/j.surg.2019.04.038

15. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. doi:10.1182/blood-2002-01-0108

16. Zangenberg MS, Horesh N, Kopylov U, El-Hussuna A. Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review. Int J Colorectal Dis. 2017;32(12):1663-1676. doi:10.1007/s00384-017-2915-4

17. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2-3):70-8. doi:10.1016/j.disamonth.2005.02.003

18. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204. doi:10.1111/j.1538-7836.2009.03678.x

19. Yam L, Bahjri K, Geslani V, Cotton A, Hong L. Enoxaparin thromboprophylaxis dosing and anti-factor Xa levels in low-weight patients. Pharmacotherapy. 2019;39(7):749-755. doi:10.1002/phar.2295

20. Rojas L, Aizman A, Ernst D, et al. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms. Thromb Res. 2013;132(6):761-764. doi:10.1016/j.thromres.2013.10.005

21. Baumgartner JM, McKenzie S, Block S, Costantini TW, Lowy AM. Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. J Surg Res. 2018;221:183-189. doi:10.1016/j.jsr.2017.08.053

22. Tahaineh L, Edaily SM, Gharibeh SF. Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. Clin Pharmacol. 2018;10:63-70. doi:10.2147/CPAA.S161599

23. He Z, Morrissey H, Ball P. Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients—actual weight-based vs fixed. Crit Rev Oncol Hematol. 2017;113:191-194. doi:10.1016/j.critrevonc.2017.03.022

24. Ritz P, Vol S, Berrut G, Tack I, Arnaud MJ, Tichet J. Influence of gender and body composition on hydration and body water spaces. Clin Nutr. 2008;27(5):740-746. doi:10.1016/j.clnu.2008.07.010

25. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143-157. doi:10.2165/00003088-200948030-00001

26. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.

27. Levin A, Ben-Artzi M, Beckerman P, et al. Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium: a prospective, open-label, observational study. Drugs Aging. 2009;26(1):77-85. doi:10.2165/0002512-200926010-00006

28. Patel KV, Darakhshan AA, Griffin N, Williams AB, Sanderson JD, Irving PM. Patient optimization for surgery relating to Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2016;13(12):707-719. doi:10.1038/nrgastro.2016.158

29. Braga M, Ljungqvist O, Soeters P, et al. ESPEN guidelines on parenteral nutrition: surgery. Clin Nutr. 2009;28(4):378-386. doi:10.1016/j.clnu.2009.04.002

30. Barco S, Atema JJ, Coppen M, Serlie MJ, Middeldorp S. Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. Blood Transfus. 2017;15(4):369-377. doi:10.2450/2016.0031-16